Despite pharma’s one-year underperformance, Sharekhan sees strong revenue growth and identifies five top stocks with 9–16% upside potential.
Source :- Markets-Economic Times Read More
Sharekhan bullish despite pharma’s underperformance; backs Cipla, Lupin & 3 more for up to 16% gains
- No Comments
- 6 Min Read
Share it :
Get free tips and resources right in your inbox, along with 10,000+ others
Categories
Latest Post
